Atlas Trials

Real-World Study on the Efficacy of IBI-322 in Combination With Lenvatinib for the Treatment of Extensive Stage Small Cell Lung Cancer

Clinical trial NCT05991180 · UNKNOWN

Trial details

NCT number
NCT05991180
Sponsor
Hunan Province Tumor Hospital
Status
UNKNOWN
Study type
OBSERVATIONAL
Extensive-stage Small-cell Lung Cancer
Start date
2023-12-25
Primary completion
2024-12-01
Enrollment
160

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.